Brind.
  1. Collegium Pharmaceutical acquired Ironshore Therapeutics in 2024 and is scheduled to present pain studies at PAINWeek 2025.

Collegium Pharmaceutical reported on August 14, 2025, that the company enjoys steady growth across its pain portfolio, driven by its successful ADHD therapy product, Jornay.

7 reports, 2 independent Updated Aug 6
Gone quiet Reached 2 outlets in its first 24 hours
Reports
7
Developments
2
Repetition
71%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Collegium Pharmaceutical reported on August 14, 2025, that the company enjoys steady growth across its pain portfolio, driven by its successful ADHD therapy product, Jornay.

Who's involved

What this event is mainly about
Collegium Pharmaceutical (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. Collegium's pain portfolio shows steady growth, supported by successful product Jornay.1 source
  2. Q1 revenue success driven by Jornay growth; analysts question seasonality.

Keep exploring

Part of

Collegium Pharmaceutical acquired Ironshore Therapeutics in 2024 and is scheduled to present pain studies at PAINWeek 2025. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • StockStoryThe 5 Most Interesting Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call Collegium Pharmaceutical’s second quarter results drew a positive market response, as management credited the
  • StockStoryCOLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results topping
  • StockStoryCollegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results beating Wall Street’s revenu
  • GlobeNewswireCollegium to Report Second Quarter 2025 Financial Results on August 7, 2025 STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it w
  • Unknown outlet
  • Unknown outlet
1 more outlet ran the same wire story